Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat valvular heart disease significantly improved survival.1 These findings were presented today at EACVI 2025, the flagship congress of the European Association of Cardiovascular Imaging (EACVI), a branch of the European Society of Cardiology (ESC).

Treatment advances have led to improved survival for patients with cancer. As patients live longer, they are at an increased risk of developing valvular heart disease after successful cancer therapy. Furthermore, it is now well recognised that certain cancer treatments can cause cardiovascular toxicity that may lead to premature morbidity among cancer survivors.

“Cardiovascular complications are becoming increasingly relevant i

See Full Page